Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2237-2249

  Breinig, Marco ^a,f   Mayer, Philipp ^a   Harjung, Andreas ^a   Goeppert, Benjamin ^a   Malz, Mona ^a   Penzel, Roland ^a   Neumann, Olaf ^a   Hartmann, Arndt ^b   Dienemann, Hendrik ^c   Giaccone, Giuseppe ^d   Schirmacher, Peter ^a   Kern, Michael Andre ^a   Chiosis, Gabriela ^e   Rieker, Ralf Joachim ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; TANESPIMYCIN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INVASION; CELL CYCLE ARREST; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYMIC EPITHELIAL TUMOR; THYMOMA; TISSUE MICROARRAY;

AGED; APOPTOSIS; BENZOQUINONES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; LACTAMS, MACROCYCLIC; MALE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THYMUS NEOPLASMS;

EID: 79954585458     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1689     Document Type: Article

References (49)

1. Rieker RJ, Hoegel J, Morresi-Hauf A, Hofmann WJ, Blaeker H, Penzel R, et al. Histologic classification of thymic epithelial tumors: comparison of established classification schemes. Int J Cancer 2002;98:900-6. (Pubitemid 34286688)
2. Strobel P, Marx A, Zettl A, Muller-Hermelink HK. Thymoma and thymic carcinoma: an update of the WHO Classification 2004. Surg Today 2005;35:805-11. (Pubitemid 41374382)
3. Rajan A, Giaccone G. Treatment of advanced thymoma and thymic carcinoma. Curr Treat Options Oncol 2008;9:277-87.
4. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006;5:649-59. (Pubitemid 44151603)
5. Ehemann V, Kern MA, Breinig M, Schnabel PA, Gunawan B, Schulten HJ, et al. Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma. Int J Cancer 2008;122:2719-25. (Pubitemid 351631373)
6. Inai K, Takagi K, Takimoto N, Okada H, Imamura Y, Ueda T, et al. Multiple inflammatory cytokine-productive ThyL-6 cell line established from a patient with thymic carcinoma. Cancer Sci 2008;99:1778-84.
7. Strobel P, Hohenberger P, Marx A. Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol 2010;5:S286-90.
8. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72. (Pubitemid 41400776)
9. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008;410:439-53. (Pubitemid 351429015)
10. Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004;82:488-99. (Pubitemid 39149859)
11. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007;1113:202-16. (Pubitemid 350015011)
12. Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: smallmolecule inhibitors and their clinical development. Curr Opin Pharmacol 2008;8:370-4.
13. Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 2009;17:2225-35.
14. Rodina A, Vilenchik M, Moulick K, Aguirre J, Kim J, Chiang A, et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat Chem Biol 2007;3:498-507. (Pubitemid 47080368)
15. Rieker RJ, Joos S, Mechtersheimer G, Blaeker H, Schnabel PA, Morresi-Hauf A, et al. COX-2 upregulation in thymomas and thymic carcinomas. Int J Cancer 2006;119:2063-70. (Pubitemid 44423662)
16. Breinig M, Caldas-Lopes E, Goeppert B, Malz M, Rieker R, Bergmann F, et al. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology 2009;50:102-12.
17. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-92. (Pubitemid 12228012)
18. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005;23:9408-21.
19. Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 2009;4:54-72.
20. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007;117:2051-8. (Pubitemid 47224766)
21. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in nonsmallcell lung cancer. J Clin Oncol 2007;25:587-95. (Pubitemid 350002967)
22. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008;14:6364-70.
23. Henley JD, Koukoulis GK, Loehrer PJ, Sr. Epidermal growth factor receptor expression in invasive thymoma. J Cancer Res Clin Oncol 2002;128:167-70.
24. Zhou R, Zettl A, Strobel P, Wagner K, Müller-Hermelink HK, Zhang S, et al. Thymic epithelial tumors can develop along two different pathogenetic pathways. Am J Pathol 2001;159:1853-60. (Pubitemid 33062527)
25. Girard N, Shen R, Guo T, Zakowski MF, Heguy A, Riely GJ, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009;15:6790-9.
26. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-37.
27. Zucali PA, Petrini I, Lorenzi E, Merino M, Cao L, Di Tommaso L, et al. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer 2010;116:4686-95.
28. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
29. Liao B, Hu Y, Herrick DJ, Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005;280:18517-24. (Pubitemid 41389102)
30. Savino W, Cotta-de-Almeida V, van Buul-Offers SC, Koster JG, Dardenne M. Abnormal thymic microenvironment in insulin-like growth factor-II transgenic mice. Neuroimmunomodulation 2005;12:100-12. (Pubitemid 40529256)
31. van Buul-Offers SC, de Haan K, Reijnen-Gresnigt MG, Meinsma D, Jansen M, Oei SL, et al. Overexpression of human insulin-like growth factor-II in transgenic mice causes increased growth of the thymus. J Endocrinol 1995;144:491-502.
32. Zhou R, Flaswinkel H, Schneider MR, Lahm H, Hoeflich A, Wanke R, et al. Insulin-like growth factor-binding protein-4 inhibits growth of the thymus in transgenic mice. J Mol Endocrinol 2004;32:349-64. (Pubitemid 38584641)
33. Chu YW, Schmitz S, Choudhury B, Telford W, Kapoor V, Garfield S, et al. Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion. Blood 2008;112:2836-46.
34. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751, 871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-40. (Pubitemid 47583908)
35. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31. (Pubitemid 33741897)
36. Hirabayashi H, Fujii Y, Sakaguchi M, Tanaka H, Yoon HE, Komoto Y, et al. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 1997;73:639-44. (Pubitemid 127483057)
37. Suzuki E, Sasaki H, Kawano O, Endo K, Haneda H, Yukiue H, et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006;36:351-6. (Pubitemid 44043923)
38. Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H, et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008;62:316-20.
39. Meister M, Schirmacher P, Dienemann H, Mechtersheimer G, Schnabel PA, Kern MA, et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett 2007;248:186-91. (Pubitemid 46330550)
40. Cichowski K, Janne PA. Drug discovery: inhibitors that activate. Nature 2010;464:358-9.
41. Amit I, Wides R, Yarden Y. Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol 2007;3:151:1-14.
42. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, et al. Identifying genotype-dependent efficacy of single and combined PI3K-and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A 2009;106:18351-6.
43. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-7. (Pubitemid 34074005)
44. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004;206:149-57. (Pubitemid 38317285)
45. Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 2009;69:1966-75.
46. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-60. (Pubitemid 351556284)
47. Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 2008;14:240-8. (Pubitemid 351378001)
48. Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 2009;106:8368-73.
49. Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med 2009;15:1369-76.